Prevention, diagnosis and treatment of cancer overexpressing GPR160

A dsRNA, wherein the dsRNA has the structure as shown in Formula II:

• wherein,
• Seq′forward is a RNA sequence corresponding to the GPR160 gene fragment sequence of SEQ ID NO:
• 6 or SEQ ID NO:
• 7;
• Seq′reverse is a sequence that is substantially complementary to Seq′forward;
• X′ is none, or a spacer sequence located between Seq′forward and Seq′reverse, and the spacer sequence is not complementary to Seq′forward and Seq′reverse,
• ll represents a hydrogen bond formed between Seq′forward and Seq′reverse.

A composition, wherein the composition contains an inhibitor inhibiting GPR160 gene expression by interfering with GPR160 gene fragment of SEQ ID NO:

• 6 or SEQ ID NO:
• 7;
• wherein the inhibitor includes:
• small interfering molecules or antisense nucleotides that specifically interfere with GPR160 gene expression.

A method for preparing dsRNA, including steps of:

• (i) preparing a construct expressing dsRNA, wherein the construct is double-stranded, and its sense or antisense strand contains the structure shown in Formula 1:
• SeqForward-X-SeqReverse Formula I
• wherein,
• Seqforward is a GPR160 gene fragment of SEQ ID NO:
• 6 or SEQ ID NO:
• 7;
• Seqreverse is a nucleotide sequence that is substantially complementary to Seqforward;
• X is a spacer sequence located between Seqforward and Seqreverse, and the spacer sequence is not complementary to Seqforward or Seqreverse;
• (ii) transferring the construct in step (i) into a host cell, thereby forming dsDNA as shown in Formula II in the host cell through expression,
• wherein,
• Seq′forward is a RNA sequence or sequence fragment corresponding to Seqforward;
• Seq′reverse is a sequence that is substantially complementary to Seq′forward;
• X′ is none, or a spacer sequence located between Seq′forward and Seq′reverse, and the spacer sequence is not complementary to Seq′forward or Seq′reverse,
• ll represents a hydrogen bond formed between Seq′forward and Seq′reverse.